About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Focusing on Patients With NSCLC, Scientists Hunting For Second-Line Defence

by Nancy Needhima on July 29, 2012 at 3:26 PM
Font : A-A+

Focusing on Patients With NSCLC, Scientists Hunting For Second-Line Defence

Concerning lung cancer, people who successfully benefit from drugs like erlotinib will certainly develop drug resistance. This is heralded by cancer growth and increasing tumor-related symptoms. Now scientists are investigating a second line of defense by studying the use of the novel AKT inhibitor MK-2206 in combination with erlotinib for patients whose benefit from erlotinib has begun to wane. Results of a Phase II trial will be presented during the 5th Latin American Conference on Lung Cancer.

Dr. Primo Lara, medical oncologist and professor of medicine at the University of California Davis Comprehensive Cancer Center in Sacramento, U.S.A, will share the latest on this research at an abstract session Friday, July 27 at 8 a.m. in the Louvre I & II rooms at the Windsor Barra Hotel.

Advertisement

Dr. Lara will present the initial efficacy and toxicity analysis of a stratified phase II trial of MK2206 plus erlotinib in two patient cohorts: those tumors with or without activating EGFR mutations. The trial, sponsored by the US National Cancer Institute through the California Cancer Consortium, has enrolled 42 patients with advanced NSCLC who have had prior benefit from erlotinib (either response or stable disease for at least 12 weeks) but have since progressed.

Dr. Lara is willing to do media interviews. The media is invited to attend all events with proper registration. All events will be simultaneously translated from English to Portuguese.
Advertisement

The 5th Latin American Conference on Lung Cancer will highlight the latest in lung cancer research and tobacco control. Nearly 1,000 medical professionals will gather at the conference to discuss the latest lung cancer research and treatment. Lung cancer kills more than 1.5 million people each year worldwide. It is also among the most challenging cancers to treat.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test your Knowledge on Heart Transplantation
Test Your Knowledge on Lung Transplantation
Baldness can be Cured and Prevented: let us see How!
View all
News Archive
Date
Category
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

Most Popular on Medindia

Sanatogen Nutam (400mg) (Piracetam) Diaphragmatic Hernia Post-Nasal Drip Calculate Ideal Weight for Infants Loram (2 mg) (Lorazepam) Daily Calorie Requirements Blood Pressure Calculator Blood - Sugar Chart Drug - Food Interactions
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
CONSULT ONLINE WITH A DOCTOR